PriceTargets.com logo

Histogen - HSTO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.35 As of 04/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for HSTO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Histogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSTO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Histogen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.35.

This chart shows the closing price for HSTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Histogen. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2022HC WainwrightLower TargetBuy$48.00 ➝ $30.00Low
8/30/2021HC WainwrightInitiated CoverageBuy$48.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Histogen logo
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $0.35
Low: $0.35
High: $0.40

50 Day Range

MA: $0.38
Low: $0.15
High: $0.50

52 Week Range

Now: $0.35
Low: $0.05
High: $1.05

Volume

6,956 shs

Average Volume

21,587 shs

Market Capitalization

$1.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Histogen?

The following equities research analysts have issued stock ratings on Histogen in the last twelve months:
View the latest analyst ratings for HSTO.

What is the current price target for Histogen?

0 Wall Street analysts have set twelve-month price targets for Histogen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Histogen in the next year.
View the latest price targets for HSTO.

What is the current consensus analyst rating for Histogen?

Histogen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HSTO.

What other companies compete with Histogen?

Other companies that are similar to Histogen include Panbela Therapeutics, GRI Bio, NeuBase Therapeutics, 180 Life Sciences and InMed Pharmaceuticals. Learn More about companies similar to Histogen.

How do I contact Histogen's investor relations team?

Histogen's physical mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The company's listed phone number is (858) 526-3100 and its investor relations email address is [email protected]. The official website for Histogen is www.histogen.com. Learn More about contacing Histogen investor relations.